News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
535,625 Results
Type
Article (45417)
Company Profile (120)
Press Release (490087)
Multimedia
Podcasts (95)
Webinars (16)
Section
Business (145354)
Career Advice (2406)
Deals (28004)
Drug Delivery (120)
Drug Development (68198)
Employer Resources (151)
FDA (15751)
Job Trends (12007)
News (264522)
Policy (29760)
Tag
Academia (2304)
Academic (1)
Accelerated approval (10)
Adcomms (32)
Allergies (93)
Alliances (36175)
ALS (106)
Alzheimer's disease (1490)
Antibody-drug conjugate (ADC) (161)
Approvals (15692)
Artificial intelligence (299)
Autoimmune disease (33)
Automation (14)
Bankruptcy (312)
Best Places to Work (9197)
BIOSECURE Act (22)
Biosimilars (126)
Biotechnology (71)
Bladder cancer (94)
Brain cancer (34)
Breast cancer (332)
Cancer (2673)
Cardiovascular disease (223)
Career advice (2015)
Career pathing (33)
CAR-T (172)
CDC (40)
Cell therapy (480)
Cervical cancer (22)
Clinical research (56208)
Collaboration (873)
Company closure (3)
Compensation (679)
Complete response letters (29)
COVID-19 (2633)
CRISPR (59)
C-suite (297)
Cystic fibrosis (107)
Data (2725)
Decentralized trials (2)
Denatured (17)
Depression (70)
Diabetes (334)
Diagnostics (5314)
Digital health (19)
Diversity (5)
Diversity, equity & inclusion (43)
Drug discovery (117)
Drug pricing (146)
Drug shortages (33)
Duchenne muscular dystrophy (125)
Earnings (59679)
Editorial (48)
Employer branding (20)
Employer resources (138)
Events (78610)
Executive appointments (773)
FDA (17360)
Fibrodysplasia Ossificans Progressiva (2)
Friedreich's ataxia (4)
Frontotemporal dementia (8)
Funding (794)
Gene editing (127)
Generative AI (25)
Gene therapy (381)
GLP-1 (861)
Government (4002)
Grass and pollen (6)
Guidances (174)
Healthcare (14856)
Huntington's disease (31)
IgA nephropathy (42)
Immunology and inflammation (176)
Immuno-oncology (10)
Indications (34)
Infectious disease (2809)
Inflammatory bowel disease (140)
Inflation Reduction Act (11)
Influenza (60)
Intellectual property (109)
Interviews (450)
IPO (14083)
IRA (52)
Job creations (3167)
Job search strategy (1668)
Kidney cancer (14)
Labor market (46)
Layoffs (548)
Leadership (25)
Legal (6990)
Liver cancer (77)
Lung cancer (374)
Lymphoma (197)
Machine learning (11)
Management (51)
Manufacturing (365)
MASH (94)
Medical device (11300)
Medtech (11303)
Mergers & acquisitions (14588)
Metabolic disorders (879)
Multiple sclerosis (89)
NASH (22)
Neurodegenerative disease (125)
Neuropsychiatric disorders (39)
Neuroscience (2152)
NextGen: Class of 2025 (4993)
Non-profit (3180)
Now hiring (22)
Obesity (465)
Opinion (233)
Ovarian cancer (90)
Pain (105)
Pancreatic cancer (113)
Parkinson's disease (184)
Partnered (17)
Patents (287)
Patient recruitment (146)
Peanut (48)
People (43144)
Pharmaceutical (33)
Pharmacy benefit managers (25)
Phase I (16830)
Phase II (24338)
Phase III (19970)
Pipeline (1580)
Policy (234)
Postmarket research (2206)
Preclinical (6833)
Press Release (28)
Prostate cancer (140)
Psychedelics (41)
Radiopharmaceuticals (220)
Rare diseases (479)
Real estate (4267)
Recruiting (61)
Regulatory (21314)
Reports (34)
Research institute (2065)
Resumes & cover letters (402)
Rett syndrome (9)
RNA editing (6)
RSV (54)
Schizophrenia (93)
Series A (146)
Series B (100)
Service/supplier (9)
Sickle cell disease (62)
Special edition (20)
Spinal muscular atrophy (130)
Sponsored (36)
Startups (2757)
State (1)
Stomach cancer (17)
Supply chain (77)
Tariffs (65)
The Weekly (77)
Vaccines (861)
Venture capital (56)
Weight loss (317)
Women's health (38)
Worklife (20)
Date
Today (84)
Last 7 days (314)
Last 30 days (1839)
Last 365 days (28788)
2025 (15486)
2024 (31410)
2023 (35000)
2022 (45088)
2021 (48510)
2020 (45519)
2019 (36224)
2018 (27410)
2017 (27824)
2016 (25811)
2015 (27994)
2014 (21802)
2013 (17803)
2012 (18975)
2011 (19398)
2010 (17525)
Location
Africa (673)
Alabama (49)
Alaska (6)
Arizona (178)
Arkansas (10)
Asia (31439)
Australia (5502)
California (6749)
Canada (1796)
China (536)
Colorado (281)
Connecticut (308)
Delaware (171)
Europe (76761)
Florida (1043)
Georgia (219)
Hawaii (2)
Idaho (37)
Illinois (532)
India (25)
Indiana (284)
Iowa (17)
Japan (204)
Kansas (87)
Kentucky (18)
Louisiana (10)
Maine (64)
Maryland (956)
Massachusetts (5057)
Michigan (202)
Minnesota (379)
Mississippi (2)
Missouri (76)
Montana (12)
Nebraska (19)
Nevada (71)
New Hampshire (54)
New Jersey (1897)
New Mexico (14)
New York (1856)
North Carolina (990)
North Dakota (7)
Northern California (3011)
Ohio (186)
Oklahoma (9)
Oregon (28)
Pennsylvania (1416)
Puerto Rico (11)
Rhode Island (23)
South America (1038)
South Carolina (33)
South Dakota (1)
Southern California (2533)
Tennessee (109)
Texas (967)
United States (24662)
Utah (176)
Virginia (167)
Washington D.C. (68)
Washington State (566)
West Virginia (4)
Wisconsin (67)
535,625 Results for "ipsen s a s".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
GENFIT to receive a €26.5 million milestone payment following the approval of pricing and reimbursement of Ipsen’s Iqirvo® in Italy
May 21, 2025
·
5 min read
Press Releases
Ipsen S.A. - Annual General Meeting held on 21 May 2025
May 22, 2025
·
6 min read
Press Releases
Ipsen S.A. - Formalities for making available and consulting preparatory documents to the 2025 Annual General Meeting
May 1, 2025
·
6 min read
Press Releases
Ipsen - Half year statement - 2025 06 30
July 8, 2025
·
5 min read
FDA
GENFIT: Historic Milestone Achieved with U.S. FDA Accelerated Approval of Ipsen’s Iqirvo® for Primary Biliary Cholangitis
GENFIT announced the achievement of a historic corporate milestone: the U.S. Food and Drug Administration accelerated approval of Iqirvo1 2 80 mg tablets – as unveiled today by Ipsen – as a first-in-class treatment for PBC in combination with ursodeoxycholic acid in adults with an inadequate response to UDCA, or as monotherapy in patients unable to tolerate UDCA.
June 10, 2024
·
15 min read
FDA
Ipsen, Genfit’s Elafibranor Wins FDA Approval for Primary Biliary Cholangitis
Ipsen and Genfit’s elafibranor will now be marketed as Iqirvo and is the first new medicine approved in nearly a decade for the treatment of the rare liver disease, according to the companies.
June 11, 2024
·
2 min read
·
Tristan Manalac
Press Releases
Ipsen receives positive CHMP opinion for Cabometyx® in previously treated advanced neuroendocrine tumors
June 20, 2025
·
13 min read
Ipsen’s Iqirvo® receives U.S. FDA accelerated approval as a first-in-class PPAR treatment for primary biliary cholangitis
Ipsen (Euronext: IPN; ADR: IPSEY) today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval for Iqirvo® (elafibranor) 80 mg tablets for the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid (UDCA) in adults who have an inadequate response to UDCA, or as monotherapy in patients unable to tolerate UDCA.
June 10, 2024
·
17 min read
Press Releases
Ipsen appoints Laura Réveillon as EVP, Strategy & Transformation
May 6, 2025
·
6 min read
Press Releases
Exelixis’ Partner Ipsen Receives Positive CHMP Opinion for CABOMETYX® (cabozantinib) for Patients with Previously Treated Advanced Neuroendocrine Tumors
June 20, 2025
·
17 min read
1 of 53,563
Next
